Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.

Because the difference in the change from baseline to end-of-study for the number of satisfying sexual events reported did not reach statistical significance between treatment groups (study 301: bremelanotide 0.0, placebo −0.1, P =.764; study 302: bremelanotide 0.0, placebo 0.0, P =.702; integrated studies: bremelanotide 0.0, placebo −0.1, P =.630), the remaining ranked secondary endpoints became supportive and exploratory per the statistical analysis plan.

also in 111,027 other papers